Literature DB >> 23498093

Identifying SNP targeted pathways in partial epilepsies with genome-wide association study data.

B Bakir-Gungor1, B Baykan, S Ugur İseri, F N Tuncer, O U Sezerman.   

Abstract

PURPOSE: In a recent genome-wide association study for partial epilepsies in the European population, a common genetic variation has been reported to affect partial epilepsy only modestly. However, in complex diseases such as partial epilepsy, multiple factors (e.g. single nucleotide polymorphisms, microRNAs, metabolic and epigenetic factors) may target different sets of genes in the same pathway, affecting its function and thus causing the disease development. In this regard, we hypothesize that the pathways are critical for elucidating the mechanisms underlying partial epilepsy.
METHODS: Previously we had developed a novel methodology with the aim of identifying the disease-related pathways. We had combined evidence of genetic association with current knowledge of (i) biochemical pathways, (ii) protein-protein interaction networks, and (iii) the functional information of selected single nucleotide polymorphisms. In our present study, we apply this methodology to a data set on partial epilepsy, including 3445 cases and 6935 controls of European ancestry.
RESULTS: We have identified 30 overrepresented pathways with corrected p-values smaller than 10(-12). These pathways include complement and coagulation cascades, cell cycle, focal adhesion, extra cellular matrix-receptor interaction, JAK-STAT signaling pathway, MAPK signaling pathway, proteasome, ribosome, calcium signaling and regulation of actin cytoskeleton pathways. Most of these pathways have growing scientific support in the literature as being associated with partial epilepsy. We also demonstrate that different factors affect distinct parts of the pathways, as shown here on complement and coagulation cascades pathway with a comparison of gene expression vs. genome-wide association study.
CONCLUSIONS: Traditional studies on genome-wide association have not revealed strong associations in epilepsies, since these single nucleotide polymorphisms are not shared by most of the patients. Our results suggest that it is more effective to incorporate the functional effect of a single nucleotide polymorphism on the gene product, protein-protein interaction networks and functional enrichment tools into genome-wide association studies. These can then be used to determine leading molecular pathways, which cannot be detected through traditional analyses. We hope that this type of analysis brings the research community one step closer to unraveling the complex genetic structure of epilepsies.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23498093     DOI: 10.1016/j.eplepsyres.2013.02.008

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  Identification of possible pathogenic pathways in Behçet's disease using genome-wide association study data from two different populations.

Authors:  Burcu Bakir-Gungor; Elaine F Remmers; Akira Meguro; Nobuhisa Mizuki; Daniel L Kastner; Ahmet Gul; Osman U Sezerman
Journal:  Eur J Hum Genet       Date:  2014-09-17       Impact factor: 4.246

2.  Whole-exome sequencing with targeted analysis and epilepsy after acute symptomatic neonatal seizures.

Authors:  Adam L Numis; Gilberto da Gente; Elliott H Sherr; Hannah C Glass
Journal:  Pediatr Res       Date:  2021-04-12       Impact factor: 3.953

3.  CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes.

Authors:  Timucin Avsar; İlknur Melis Durası; Uğur Uygunoğlu; Melih Tütüncü; Nuri Onat Demirci; Sabahattin Saip; O Uğur Sezerman; Aksel Siva; Eda Tahir Turanlı
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

4.  pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks.

Authors:  Ege Ulgen; Ozan Ozisik; Osman Ugur Sezerman
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.